

Martin Strassnig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/245951/publications.pdf>

Version: 2024-02-01

43
papers

1,994
citations

236612

25
h-index

253896

43
g-index

43
all docs

43
docs citations

43
times ranked

2570
citing authors

#	ARTICLE	IF	CITATIONS
1	Depression, hostility, attributional biases, and paranoia in schizophrenia and healthy controls: intercorrelations and associations with self-assessment of social functioning. <i>Psychiatry Research</i> , 2020, 293, 113388.	1.7	1
2	O6.6. REAL WORLD SEDENTARY BEHAVIOR AND ACTIVITY LEVELS IN PATIENTS WITH SCHIZOPHRENIA AND CONTROLS DERIVED FROM ECOLOGICAL MOMENTARY ASSESSMENT. <i>Schizophrenia Bulletin</i> , 2019, 45, S178-S178.	2.3	3
3	Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. <i>Schizophrenia Research</i> , 2019, 208, 182-189.	1.1	22
4	Associations of independent living and labor force participation with impairment indicators in schizophrenia and bipolar disorder at 20-year follow-up. <i>Schizophrenia Research</i> , 2018, 197, 150-155.	1.1	44
5	Tardive dyskinesia: motor system impairments, cognition and everyday functioning. <i>CNS Spectrums</i> , 2018, 23, 370-377.	0.7	28
6	Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia?. <i>Journal of Psychiatric Research</i> , 2018, 104, 124-129.	1.5	63
7	Body composition, pre-diabetes and cardiovascular disease risk in early schizophrenia. <i>Microbial Biotechnology</i> , 2017, 11, 229-236.	0.9	16
8	Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. <i>Bipolar Disorders</i> , 2017, 19, 336-343.	1.1	52
9	Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder. <i>Journal of Psychiatric Research</i> , 2017, 94, 180-185.	1.5	24
10	Absence of bias in clinician ratings of everyday functioning among African American, Hispanic and Caucasian patients with schizophrenia. <i>Psychiatry Research</i> , 2015, 229, 347-352.	1.7	6
11	Factors influencing self-assessment of cognition and functioning in schizophrenia: Implications for treatment studies. <i>European Neuropsychopharmacology</i> , 2015, 25, 185-191.	0.3	75
12	Physical performance and disability in schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2014, 1, 112-121.	0.7	56
13	Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. <i>Bipolar Disorders</i> , 2014, 16, 422-431.	1.1	71
14	The course of vocational functioning in patients with schizophrenia: Re-examining social drift. <i>Schizophrenia Research: Cognition</i> , 2014, 1, e41-e46.	0.7	17
15	Diabetes Resolution Following Discontinuation of a Second-Generation Antipsychotic. <i>Clinical Schizophrenia and Related Psychoses</i> , 2013, 6, 202-203.	1.4	5
16	Treatment of obesity and disability in schizophrenia. <i>Innovations in Clinical Neuroscience</i> , 2013, 10, 15-9.	0.1	1
17	Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. <i>World Psychiatry</i> , 2012, 11, 73-79.	4.8	233
18	Cognitive deficits, obesity and disability in schizophrenia. <i>Translational Neuroscience</i> , 2012, 3, .	0.7	8

#	ARTICLE	IF	CITATIONS
19	Health-related quality of life, adiposity, and sedentary behavior in patients with early schizophrenia: preliminary study. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , 2012, 5, 389.	1.1	9
20	Low cardiorespiratory fitness and physical functional capacity in obese patients with schizophrenia. <i>Schizophrenia Research</i> , 2011, 126, 103-109.	1.1	85
21	Changes in cigarette consumption in psychiatric patients: impact on side-effects or the efficacy of clozapine and olanzapine. <i>Acta Neuropsychiatrica</i> , 2008, 20, 324-326.	1.0	4
22	Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: One-year analysis. <i>Schizophrenia Research</i> , 2007, 93, 90-98.	1.1	106
23	Decreased T cellular immune response in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2007, 41, 3-7.	1.5	70
24	Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 360-370.	1.8	47
25	Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 402-412.	1.8	40
26	Predictive eye and hand movements are differentially affected by schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 413-422.	1.8	8
27	Quetiapine in the treatment of schizophrenia and related disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2007, 3, 219-235.	1.0	56
28	Weight Loss Interventions for Patients with Schizophrenia. <i>Clinical Schizophrenia and Related Psychoses</i> , 2007, 1, 43-53.	1.4	7
29	Increased caffeine and nicotine consumption in community-dwelling patients with schizophrenia. <i>Schizophrenia Research</i> , 2006, 86, 269-275.	1.1	64
30	General medical and psychiatric perspectives on somatoform disorders: separated by an uncommon language. <i>Current Opinion in Psychiatry</i> , 2006, 19, 194-200.	3.1	26
31	Are older antipsychotic drugs obsolete?. <i>BMJ: British Medical Journal</i> , 2006, 332, 1346-1347.	2.4	12
32	How representative of everyday clinical populations are schizophrenia patients enrolled in clinical trials?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 143-148.	1.8	53
33	Risperidone plasma levels, clinical response and side-effects. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 261-268.	1.8	111
34	Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 432-437.	1.8	49
35	ICAM G241A Polymorphism and Soluble ICAM-1 Serum Levels: Evidence for an Active Immune Process in Schizophrenia. <i>NeuroImmunoModulation</i> , 2005, 12, 54-59.	0.9	31
36	COX-2 Inhibitors as Adjunctive Therapy in Schizophrenia. <i>CNS Drugs</i> , 2005, 19, 805-819.	2.7	39

#	ARTICLE	IF	CITATIONS
37	Self-reported body weight perception and dieting practices in community-dwelling patients with schizophrenia. <i>Schizophrenia Research</i> , 2005, 75, 425-432.	1.1	40
38	Dietary fatty acid and antioxidant intake in community-dwelling patients suffering from schizophrenia. <i>Schizophrenia Research</i> , 2005, 76, 343-351.	1.1	52
39	Dietary intake of patients with schizophrenia. <i>Psychiatry</i> , 2005, 2, 31-5.	0.3	4
40	COX-2 inhibitors as adjunctive therapy in schizophrenia. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1033-1044.	1.9	35
41	Electroconvulsive Therapy in a Patient with Tourette's Syndrome and Co-morbid Obsessive Compulsive Disorder. <i>World Journal of Biological Psychiatry</i> , 2004, 5, 164-166.	1.3	57
42	Body mass index and quality of life in community-dwelling patients with schizophrenia. <i>Schizophrenia Research</i> , 2003, 62, 73-76.	1.1	115
43	Nutritional Assessment of Patients With Schizophrenia: A Preliminary Study. <i>Schizophrenia Bulletin</i> , 2003, 29, 393-397.	2.3	149